JP2016540505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540505A5 JP2016540505A5 JP2016533143A JP2016533143A JP2016540505A5 JP 2016540505 A5 JP2016540505 A5 JP 2016540505A5 JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016540505 A5 JP2016540505 A5 JP 2016540505A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- cancer
- replication competent
- competent oncolytic
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907860P | 2013-11-22 | 2013-11-22 | |
| US61/907,860 | 2013-11-22 | ||
| PCT/US2014/066920 WO2015077624A1 (en) | 2013-11-22 | 2014-11-21 | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238013A Division JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540505A JP2016540505A (ja) | 2016-12-28 |
| JP2016540505A5 true JP2016540505A5 (enExample) | 2017-12-28 |
Family
ID=53180213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533143A Withdrawn JP2016540505A (ja) | 2013-11-22 | 2014-11-21 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2019238013A Pending JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2021097883A Pending JP2021137029A (ja) | 2013-11-22 | 2021-06-11 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238013A Pending JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2021097883A Pending JP2021137029A (ja) | 2013-11-22 | 2021-06-11 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160289645A1 (enExample) |
| EP (2) | EP3071697B1 (enExample) |
| JP (3) | JP2016540505A (enExample) |
| KR (1) | KR20160137946A (enExample) |
| CN (2) | CN114317461A (enExample) |
| AU (1) | AU2014352749A1 (enExample) |
| CA (1) | CA2931322A1 (enExample) |
| DK (1) | DK3071697T3 (enExample) |
| ES (1) | ES2765489T3 (enExample) |
| SG (1) | SG10201907841UA (enExample) |
| WO (1) | WO2015077624A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4663241A3 (en) | 2010-10-08 | 2026-03-25 | Mesoblast International Sàrl | Enhanced msc preparations |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| SG11201602887QA (en) | 2013-10-25 | 2016-05-30 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| SG11201708604TA (en) | 2015-04-30 | 2017-11-29 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
| AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| CN108135934B (zh) * | 2015-10-19 | 2024-09-10 | 永恒生物科技股份有限公司 | 通过组合疗法治疗实体或淋巴肿瘤的方法 |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| WO2017118866A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Engineered virus |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| ES3041500T3 (en) | 2016-03-10 | 2025-11-12 | Cg Oncology Inc | Methods of treating solid tumors by combination therapy |
| CN109789177A (zh) * | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| MY197324A (en) | 2016-08-29 | 2023-06-13 | Akamis Bio Ltd | Adenovirus armed with bispecific t cell activator |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| LT3293201T (lt) * | 2016-09-12 | 2021-03-25 | Targovax Oy | Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN110381997A (zh) * | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| JP2020504767A (ja) * | 2016-12-21 | 2020-02-13 | メムゲン，エルエルシー | 武装した複製可能な腫瘍溶解性アデノウイルス |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| US11548930B2 (en) | 2017-04-04 | 2023-01-10 | Heat Biologics, Inc. | Intratumoral vaccination |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| CN109276580B (zh) | 2017-07-21 | 2021-08-24 | 厦门大学 | 一种用于治疗肿瘤的病毒 |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
| CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
| CN109985241B (zh) * | 2017-12-29 | 2024-10-18 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| US12295976B2 (en) | 2018-03-28 | 2025-05-13 | Epicentrx, Inc. | Personalized cancer vaccines |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| MX2021003013A (es) * | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113710810A (zh) * | 2019-02-21 | 2021-11-26 | 安利舒免疫溶瘤技术公司 | 溶瘤腺病毒载体和使用方法 |
| CN114423860A (zh) | 2019-08-05 | 2022-04-29 | 迈索布拉斯特国际有限公司 | 包含病毒载体的细胞组合物及治疗方法 |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| CA3170045A1 (en) * | 2020-03-06 | 2021-09-10 | Saumendra N. SARKAR | Irf modulator-expressing oncolytic viruses for treating cancer |
| EP4164683A4 (en) * | 2020-06-10 | 2025-03-26 | Richard Lowenthal | GENETICALLY ENGINEERED ADENOVIRUS VECTORS AND USES THEREOF |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN115996735A (zh) | 2020-08-10 | 2023-04-21 | 迈索布拉斯特国际有限公司 | 细胞组合物和治疗方法 |
| JP7614980B2 (ja) | 2021-08-25 | 2025-01-16 | 三菱重工航空エンジン株式会社 | 燃焼器パネル、及びガスタービン用燃焼器 |
| JP2025536260A (ja) | 2022-10-11 | 2025-11-05 | イェール ユニバーシティー | 細胞透過性抗体の組成物および使用方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| EP0821739B1 (en) | 1995-04-17 | 2003-06-18 | The Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| CA2311574A1 (en) * | 1997-12-02 | 1999-06-10 | Medarex, Inc. | Cells expressing anti-fc receptor binding components |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US7368527B2 (en) * | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| EP1470233A1 (en) * | 2002-02-01 | 2004-10-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| NZ536746A (en) | 2002-06-13 | 2007-02-23 | Crucell Holland Bv | An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| US7736644B2 (en) | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| CA2597329C (en) * | 2005-02-08 | 2016-10-11 | Board Of Regents, The University Of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
| ES2605380T3 (es) | 2005-05-06 | 2017-03-14 | Providence Health & Services - Oregon | Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| KR101361416B1 (ko) * | 2008-10-08 | 2014-02-21 | 인트렉손 코포레이션 | 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2012027328A2 (en) * | 2010-08-23 | 2012-03-01 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| EP2619224A1 (en) * | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| CA2827530C (en) * | 2011-02-17 | 2019-12-03 | Arconic Technologies Llc | 2xxx series aluminum lithium alloys |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| DK2806883T3 (da) * | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| US11155599B2 (en) * | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
-
2014
- 2014-11-21 KR KR1020167016399A patent/KR20160137946A/ko not_active Ceased
- 2014-11-21 EP EP14864921.3A patent/EP3071697B1/en active Active
- 2014-11-21 US US15/038,446 patent/US20160289645A1/en not_active Abandoned
- 2014-11-21 WO PCT/US2014/066920 patent/WO2015077624A1/en not_active Ceased
- 2014-11-21 EP EP19203386.8A patent/EP3653714A1/en not_active Withdrawn
- 2014-11-21 DK DK14864921.3T patent/DK3071697T3/da active
- 2014-11-21 JP JP2016533143A patent/JP2016540505A/ja not_active Withdrawn
- 2014-11-21 CN CN202111419932.6A patent/CN114317461A/zh active Pending
- 2014-11-21 SG SG10201907841U patent/SG10201907841UA/en unknown
- 2014-11-21 CN CN201480073813.1A patent/CN106029889A/zh active Pending
- 2014-11-21 AU AU2014352749A patent/AU2014352749A1/en not_active Abandoned
- 2014-11-21 CA CA2931322A patent/CA2931322A1/en not_active Abandoned
- 2014-11-21 ES ES14864921T patent/ES2765489T3/es active Active
-
2018
- 2018-06-27 US US16/020,738 patent/US20190093085A1/en not_active Abandoned
-
2019
- 2019-12-27 JP JP2019238013A patent/JP2020048582A/ja active Pending
-
2021
- 2021-06-11 JP JP2021097883A patent/JP2021137029A/ja active Pending
- 2021-06-11 US US17/304,006 patent/US20210301264A1/en not_active Abandoned
-
2024
- 2024-10-10 US US18/912,157 patent/US20250171745A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250171745A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| ES2971065T3 (es) | Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control | |
| Lemay et al. | Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine | |
| JP2015506704A5 (enExample) | ||
| CN107847534B (zh) | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 | |
| Koske et al. | Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment | |
| AU2017207532A1 (en) | Oncolytic virus and checkpoint inhibitor combination therapy | |
| EP3400293A1 (en) | Modified oncolytic virus | |
| CN117731763A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| EP3829627A1 (en) | Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| US12611444B2 (en) | IL-36 cytokine expressing oncolytic viruses for treating cancer | |
| US20240325473A1 (en) | Cancer Treatments | |
| CA3060516C (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| Olsen et al. | Neuro-Oncology Advances | |
| Witt | Cripto-1: potential target for cancer immunotherapy?! | |
| HK40097178A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK40030022A (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Rajani et al. | Viral platforms for expression of tumor antigens in cancer immunotherapy | |
| HK1230236A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Lohr et al. | Experimental treatment of pancreatic cancer | |
| HK40025045B (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK40025045A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK1252730B (en) | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |